Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 27571-27580 Newer>

The Motley Fool December 6, 2007 Rick Aristotle Munarriz	Dueling Fools: Crocs Bull Rebuttal The bulls argue that Crocs' valuation is not high considering the company's rapid growth of revenue and earnings in the past year.
The Motley Fool December 6, 2007 Kristin Graham	Dueling Fools: Crocs Bear Rebuttal The bears argue that just because Crocs is expanding its selection of products doesn't mean it is immune to being deemed a faddish brand.
The Motley Fool December 6, 2007 Kristin Graham	Dueling Fools: Crocs Bear The bearish argument regarding shoe manufacturer Crocs is that the stock, like its shoes, is full of holes.
The Motley Fool December 6, 2007 Rich Smith	Quick Take: Nokia's Path to Profit According to the Wall Street Journal, the Federal Trade Commission has just approved Nokia's $8.1 billion purchase of digital mapmaker Navteq.
The Motley Fool December 6, 2007 Anders Bylund	Fool on the Street: eBay's Two Smokin' Barrels eBay CFO Bob Swan discusses the company's future challenges and goals.
The Motley Fool December 6, 2007 Alyce Lomax	Zumiez Is Going Fakie, Again Is negativity about the fashion retailer overdone?
The Motley Fool December 6, 2007 Rich Duprey	Ashford's Solid Share Count Investors might want to take a closer look at Ashford Hospitality Trust, a real estate investment trust that invests in the hospitality industry. The company is gobbling up its own shares.
The Motley Fool December 6, 2007 Christopher Singley	First Marblehead Showing Cracks? Bond rating agency Moody's expresses concerns about student loan performance in securitizations facilitated by First Marblehead.
The Motley Fool December 6, 2007 Rick Aristotle Munarriz	Can a Slacker Take Down Satellite Radio? XM and Sirius are set to bump against the Slacker. While it won't be a disruptive force overnight, one can easily see it as a gradual market-share nibbler.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
<Older 27571-27580 Newer> Return to current articles.